10x Genomics, Inc. (TXG)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 70M 140M 210M Q3 '21: 125.3M Q4 '21: 143.5M Q1 '22: 114.5M Q2 '22: 114.6M Q3 '22: 131.1M Q4 '22: 156.2M Q1 '23: 134.3M Q2 '23: 146.8M Q3 '23: 153.6M Q4 '23: 184M Q1 '24: 141M Q2 '24: 153.1M Q3 '24: 151.7M Q4 '24: 165M Q1 '25: 154.9M Q2 '25: 172.9M Q3 '25: 149M Q4 '25: 166M Q1 '26: 150.8M Q2 '26: 151M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 50M 100M 150M Q3 '21: 100.8M Q4 '21: 115.9M Q1 '22: 89M Q2 '22: 86.9M Q3 '22: 100.7M Q4 '22: 119.4M Q1 '23: 98.4M Q2 '23: 99.6M Q3 '23: 95.5M Q4 '23: 115.8M Q1 '24: 92.9M Q2 '24: 104.2M Q3 '24: 106.4M Q4 '24: 111M Q1 '25: 105.4M Q2 '25: 125.1M Q3 '25: 100.3M Q4 '25: 113M Q1 '26: 106.2M Q2 '26: 112.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -15.9M Q4 '21: -15.8M Q1 '22: -41.7M Q2 '22: -63.1M Q3 '22: -40M Q4 '22: -23.1M Q1 '23: -52M Q2 '23: -63.4M Q3 '23: -94.8M Q4 '23: -55.2M Q1 '24: -61.5M Q2 '24: -41.7M Q3 '24: -41.5M Q4 '24: -49.8M Q1 '25: -39.3M Q2 '25: 30.1M Q3 '25: -32.2M Q4 '25: -19.5M Q1 '26: -17M Q2 '26: -19.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -17.2M Q4 '21: -18.4M Q1 '22: -42.4M Q2 '22: -64.5M Q3 '22: -41.9M Q4 '22: -17.2M Q1 '23: -50.7M Q2 '23: -62.4M Q3 '23: -93M Q4 '23: -49M Q1 '24: -59.9M Q2 '24: -37.9M Q3 '24: -35.8M Q4 '24: -49M Q1 '25: -34.4M Q2 '25: 34.5M Q3 '25: -27.5M Q4 '25: -16.3M Q1 '26: -13.5M Q2 '26: -17.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 25M 50M 75M Q3 '21: 24.5M Q4 '21: 27.6M Q1 '22: 25.5M Q2 '22: 27.7M Q3 '22: 30.4M Q4 '22: 36.8M Q1 '23: 35.9M Q2 '23: 47.2M Q3 '23: 58.1M Q4 '23: 68.2M Q1 '24: 48.1M Q2 '24: 48.9M Q3 '24: 45.3M Q4 '24: 54.1M Q1 '25: 49.4M Q2 '25: 47.8M Q3 '25: 48.7M Q4 '25: 53M Q1 '26: 44.7M Q2 '26: 38.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-30M -15M 0 15M 30M 45M Q3 '21: -26.2M Q4 '21: 5.8M Q1 '22: -20.8M Q2 '22: -17M Q3 '22: -9.6M Q4 '22: 13.7M Q1 '23: -4.1M Q2 '23: -11.5M Q3 '23: -25.3M Q4 '23: 25.8M Q1 '24: -15.7M Q2 '24: 7.5M Q3 '24: 21.6M Q4 '24: -6.7M Q1 '25: 34.4M Q2 '25: 17.7M Q3 '25: 43.2M Q4 '25: 40.8M Q1 '26: 26.1M Q2 '26: 17M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -46.4M Q4 '21: -21.8M Q1 '22: -48.9M Q2 '22: -44.2M Q3 '22: -46.1M Q4 '22: -26M Q1 '23: -8.7M Q2 '23: -36.9M Q3 '23: -40.5M Q4 '23: 22.3M Q1 '24: -18.6M Q2 '24: 4.6M Q3 '24: 17.8M Q4 '24: -9.5M Q1 '25: 32.5M Q2 '25: 16.1M Q3 '25: 42.5M Q4 '25: 39M Q1 '26: 24.5M Q2 '26: 15.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '20: 96.8M Q2 '20: 99M Q3 '20: 101.3M Q1 '21: 108.7M Q2 '21: 109.9M Q3 '21: 110.9M Q1 '22: 113M Q2 '22: 113.6M Q3 '22: 114.1M Q1 '23: 115.6M Q2 '23: 116.7M Q3 '23: 117.7M Q1 '24: 119.4M Q2 '24: 120.1M Q3 '24: 120.7M Q1 '25: 122.6M Q2 '25: 124.5M Q3 '25: 125.5M Q1 '26: 128.3M Q2 '26: 130M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '21: -4.45 Q4 '21: -0.53 Q1 '22: -0.80 Q2 '22: -1.27 Q3 '22: -1.49 Q4 '22: -1.47 Q1 '23: -1.53 Q2 '23: -1.49 Q3 '23: -1.91 Q4 '23: -2.17 Q1 '24: -2.23 Q2 '24: -2.02 Q3 '24: -1.53 Q4 '24: -1.53 Q1 '25: -1.31 Q2 '25: -0.71 Q3 '25: -0.63 Q4 '25: -0.35 Q1 '26: -0.17 Q2 '26: -0.59 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.